跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
姜 紹青
助理教授
藥學系
電話
(02)2826-7000#65688
電子郵件
scchiang316
nycu.edu
tw
h-index
h10-index
h5-index
43
引文
4
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
32
引文
4
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
28
引文
3
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2004
2024
每年研究成果
概覽
指紋
網路
研究成果
(22)
類似的個人檔案
(6)
指紋
查看啟用 Shao-Chin Chiang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Taiwan
100%
Granulocyte Colony-stimulating Factor (G-CSF)
68%
Hazardous Drugs
67%
Safe Handling
45%
Breast Cancer
44%
Chemotherapy
35%
Antineoplastic Agents
34%
Patients with Breast Cancer
33%
Multidisciplinary Consensus
30%
Chemotherapy-induced Neutropenia
30%
Metastatic Breast Cancer
30%
Consensus Guidelines
30%
Taiwan National Health Insurance
30%
Biosimilar
30%
Primary Prophylaxis
28%
Antineoplastic Drugs
25%
Pharmacist
23%
Neutropenic
23%
Closed-system Transfer Device
21%
Women with Breast Cancer
20%
Chemotherapy Administration
20%
Cost-effectiveness
20%
Healthcare Professionals
18%
Taiwanese
18%
Chemotherapy Treatment
17%
Febrile Neutropenia
17%
Cancer Patients
16%
Best Possible Medication History
15%
PharmaCloud
15%
Prescription Pattern
15%
Pazopanib
15%
Microglial M2 Polarization
15%
National Health System
15%
Matched Cohort Study
15%
Non-Hodgkin Lymphoma
15%
Health Care Costs
15%
Lymphoma Patients
15%
Risk Assessment Tool
15%
Cancer Chemotherapy
15%
Practice Management
15%
Cancer Pharmacotherapy
15%
Handling Practices
15%
Clinical Pharmacy
15%
Drug Handling
15%
Health State Utility
15%
Evidence-based Risk Assessment
15%
Metastatic Renal Cell Carcinoma (mRCC)
15%
National Survey
15%
Clinical Conditions
15%
Chemotherapy Drugs
15%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
74%
Chemotherapy
71%
Hazardous Drugs
68%
Granulocyte Colony Stimulating Factor
52%
Febrile Neutropenia
39%
Malignant Neoplasm
30%
Metastatic Breast Cancer
30%
Nonhodgkin Lymphoma
15%
Kidney Metastasis
15%
Cohort Study
15%
Pharmacotherapy
15%
Neutropenia
15%
Health Status
15%
Pazopanib
15%
Drug System
15%
Lipopolysaccharide-Induced Neuroinflammation
15%
Ellagic Acid
15%
Lipopolysaccharide
13%
Antineoplastic Agent
9%
Sunitinib
8%
Pegfilgrastim
8%
Compounding
8%
Adverse Drug Reaction
6%
Clinical Trial
6%
Nervous System Inflammation
6%
Antibiotic as 48
5%
Vomiting
5%
Lenograstim
5%
Nursing and Health Professions
Practice Guideline
77%
Breast Cancer
59%
Hazardous Drugs
49%
Granulocyte Colony Stimulating Factor
40%
Metastatic Breast Cancer
30%
Neutropenia
30%
National Health Insurance
20%
Cohort Analysis
20%
Hospital Organization
15%
Medication Therapy Management
15%
Health Status
15%
Health Care Cost
15%
Febrile Neutropenia
13%
World Health Organization
11%
Health Care Personnel
11%
Predictive Value
10%
Logistic Regression Analysis
10%
Staff Training
9%
Malignant Neoplasm
7%
Protective Equipment
6%
Periodic Medical Examination
6%
Adverse Drug Reaction
6%
Odds Ratio
6%
Visual Analog Scale
6%
Outpatient
6%
Medication Error
6%
Cost Utility Analysis
5%
Infection
5%
Confidence Interval
5%
Nursing Assessment
5%
Patient Assessment
5%
